JNJ vs MRVL: Which Is the Better Buy?
Side-by-side comparison of Johnson & Johnson and Marvell Technology, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
VS
Marvell Technology, Inc. · Technology
$258.95
-11.4% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
JNJ has more upside to fair value
(+5.7%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JNJ |
MRVL |
| Current Price |
$270.68 |
$258.95 |
| Fair Value Estimate |
$286.05 |
$229.46 |
| Upside to Fair Value |
+5.7%
|
-11.4%
|
| Market Cap |
$652.3B |
$226.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
20.2x
|
48.0x
|
| Price / Sales |
6.7x
|
24.0x
|
| Price / FCF |
35.3x
|
134.3x
|
| Revenue Growth YoY |
+6.6%
|
+36.5%
|
| Gross Margin |
67.9%
|
51.4%
|
| Operating Margin |
26.8%
|
16.7%
|
| Return on Equity |
25.7%
|
16.2%
|
| Dividend Yield |
1.95% |
0.09% |
| FCF Yield |
2.83%
|
0.74%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Marvell Technology is a data infrastructure semiconductor specialist that designs custom AI accelerators, electro-optics DSPs, ethernet switching, storage controllers and interconnect silicon for hyperscale data centers, communications and carrier markets, employing roughly 7,480 people under CEO Matthew J. Murphy. Business quality is genuinely high on the demand side: revenue grew 36.5% year ove…
Accumulation Zones
| Metric |
JNJ |
MRVL |
| Zone Low |
$214.54 |
$172.09 |
| Zone High |
$243.14 |
$195.04 |
| In Buy Zone? |
No
|
No
|